Evidence map›Paper›PMID 32754276›Full record

ArticleTheranostics2020

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.

Abigail R Molloy, Chloé Najac, Pavithra Viswanath, Aliya Lakhani, Elavarasan Subramani, Georgios Batsios, Marina Radoul, Anne Marie Gillespie, Russell O Pieper, Sabrina M Ronen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Targeting IDH-Mutant Glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Glutamine Imaging: A New Avenue for Glioma Management.AJNR. American journal of neuroradiology · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Abigail R MolloyDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Chloé NajacDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Pavithra ViswanathDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Aliya LakhaniDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Elavarasan SubramaniDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Georgios BatsiosDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Marina RadoulDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Anne Marie GillespieDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Russell O PieperBrain Tumor Center, University of California San Francisco, San Francisco, CA, USA.
Sabrina M RonenDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
University of California System · USUniversity of California, San Francisco · USNeurological Surgery · US

Funding

TR&D3: Open-Source Tools for Processing Hyperpolarized MR DataP41EB013598 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUAN XU · 2011 to 2026
$19.9M
Metabolic Reprogramming in Brain TumorsR01CA172845 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RONEN, SABRINA MIRIAM · 2013 to 2022
$6.3M
Metabolic Imaging of Brain Tumor Response to TherapyR01CA197254 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RONEN, SABRINA MIRIAM · 2016 to 2020
$3.2M
NCI NIH HHS R01 CA172845NCI NIH HHS R01 CA197254NIBIB NIH HHS P41 EB013598
6 · The paper itself

Abstract

Mutations in isocitrate dehydrogenase 1 (IDH1mut) are reported in 70-90% of low-grade gliomas and secondary glioblastomas. IDH1mut catalyzes the reduction of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), an oncometabolite which drives tumorigenesis. Inhibition of IDH1mut is therefore an emerging therapeutic approach, and inhibitors such as AG-120 and AG-881 have shown promising results in phase 1 and 2 clinical studies. However, detection of response to these therapies prior to changes in tumor growth can be challenging. The goal of this study was to identify non-invasive clinically translatable metabolic imaging biomarkers of IDH1mut inhibition that can serve to assess response.

Indexed as

Antineoplastic AgentsBiomarkers, TumorBrain NeoplasmsCarbon-13 Magnetic Resonance SpectroscopyCell Line, TumorDiaminesGliomaGlutamic AcidGlutaratesGlycineHumansIsocitrate DehydrogenaseMutationProton Magnetic Resonance SpectroscopyPyridinesalpha-hydroxyglutarateAntineoplastic AgentsBiomarkers, TumorDiaminesGlutamic AcidGlutaratesGlycineIDH1 protein, humanIsocitrate DehydrogenaseivosidenibPyridinesvorasidenibAG-120AG-881hyperpolarized 13C magnetic resonance spectroscopyIDH1 mutationlow grade glioma

Identifiers

PMID32754276
PMCPMC7392019
OpenAlexW3045093497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.